Holen Sie sich die Stockscreener-App
6.6953
0.45%
-0.0247
Schlusskurs vom Vortag:
$6.72
Offen:
$6.69
24-Stunden-Volumen:
3.55M
Relative Volume:
0.80
Marktkapitalisierung:
$1.41B
Einnahmen:
$557.51M
Nettoeinkommen (Verlust:
$-35.71M
KGV:
-37.20
EPS:
-0.18
Netto-Cashflow:
$15.50M
1W Leistung:
-6.69%
1M Leistung:
-12.09%
6M Leistung:
-22.66%
1J Leistung:
-12.20%
1-Tages-Spanne:
$6.63
$6.8654
1-Wochen-Bereich:
$6.46
$7.17
52-Wochen-Spanne:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.695 | 1.42B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
124.18 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.66 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.62 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Astria stockholders approve acquisition by BioCryst - Investing.com Nigeria
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria stockholders vote to approve acquisition by BioCryst - marketscreener.com
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Does BioCryst (BCRX) 2026 Revenue Guidance Reframe the ORLADEYO Growth Story for Investors? - simplywall.st
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its New 2026 Revenue Guidance - Sahm
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8%What's Next? - MarketBeat
Stock Recap: What is The OLB Group Incs P E ratio telling us2025 Macro Impact & Smart Money Movement Alerts - baoquankhu1.vn
(BCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Aug Volume: Why BioCryst Pharmaceuticals Inc stock could outperform in 2025 - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc stock outperform growth indexes2025 Momentum Check & Reliable Momentum Entry Alerts - Bộ Nội Vụ
BioCryst stock holds steady as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com UK
Citizens reiterates Market Outperform rating on BioCryst Pharma stock By Investing.com - Investing.com Canada
BioCryst reports $563 million in ORLADEYO revenue for 2025 By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - MarketBeat
Investment Report: Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zoneMarket Sentiment Review & Weekly Watchlist of Top Performers - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & AI Enhanced Trading Signals - Bộ Nội Vụ
BCRX: ORLADEYO growth, Astria acquisition, and pipeline advances drive rare disease expansion - TradingView — Track All Markets
BioCryst reports $563 million in ORLADEYO revenue for 2025 - Investing.com
BCRX Forecasts FY26 ORLADEYO Revenue in Range of $625M-$645M - GuruFocus
BCRX: ORLADEYO Sees Strong Revenue Growth in Q4 2025 - GuruFocus
(BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M - marketscreener.com
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - The Manila Times
Once-daily pill for HAE patients now brings in $601M a year - Stock Titan
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play - MSN
Published on: 2026-01-10 14:45:46 - Улправда
FDA approves seven NMEs in December - biocentury.com
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility - Sahm
BioCryst Pharmaceuticals, Inc.Common Stock (NQ: BCRX - FinancialContent
BioCryst to buy Astria Therapeutics for $13 per share (update) - MSN
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack - Investing.com Nigeria
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack By Investing.com - Investing.com South Africa
BioCryst Raises Price of Key ORLADEYO Treatment - TipRanks
BioCryst Pharmaceuticals Increases ORLADEYO® Price - TradingView — Track All Markets
Is BioCryst Pharmaceuticals Inc. stock oversold or undervalued2025 Trading Recap & AI Forecasted Entry and Exit Points - ulpravda.ru
How BioCryst Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - Улправда
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsGap Down & Free Verified High Yield Trade Plans - ulpravda.ru
CEO Moves: Will BioCryst Pharmaceuticals Inc. stock deliver long term returnsPortfolio Update Report & Expert Verified Movement Alerts - Улправда
HC Wainwright lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 from $30 - MSN
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Yahoo Finance
RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - The Malaysian Reserve
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Inves - GuruFocus
BioCryst reports inducement grants under Nasdaq listing rule - MSN
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
BioCryst Pharmaceuticals Q2 2025 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocryst Pharmaceuticals Inc-Aktie (BCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gayer Charles K | President and CCO |
Dec 22 '25 |
Option Exercise |
5.01 |
74,233 |
371,896 |
952,583 |
3.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):